A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis

Table 1 Comparison of the clinical characteristics of pulmonary arterial hypertension and non-pulmonary hypertension groups

Characteristics at the time of screening	PAH	Non-PH	P value
	(n = 27)	(n = 34)
	Mean ± SD or n (%)	Mean ± SD or n (%)
Age at disease onset, years ^a	52.9 ± 14.7	48.6 ± 13.2	0.256
Age at study, years	66.8 ± 8.3	61.2 ± 11.9	0.033
Disease duration at study, years	14.9 ± 12.6	12.8 ± 10.4	0.566
Disease duration at study, years	13.0 (3.2-21.9)^b	10.3 (4.4-18.2)^b	0.566
Female	25 (93)	16 (76)	0.027
SSc subtypes
Limited	23 (85)	27 (79)	0.560
Diffuse	4 (15)	7 (21)	0.560
Telangiectasia	24 (89)	23 (68)	0.049
Antibodies
ANA	24 (89)	27 (90)	0.617
Anti-Scl70	1 (4)	3 (10)	0.373
Anti-cent	17 (63)	11 (32)	0.017
NT-proBNP, pg/mL	1,619.6 ± 2,063.6	401.3 ± 689.4	<0.0001
NT-proBNP, pg/mL	841 (531.3-2,022.1)^b	143.6 (83.3-414.2)^b	<0.0001
Serum urate, mg/100 mL	6.7 ± 2.2	5.6 ± 1.8	0.038
6MWD, m	310.4 ± 115.8	411.0 ± 114.2	0.003

^aDisease onset defined as the date of first non-Raynaud’s symptom. ^bMedian (interquartile range). 6MWD, six-minute walk distance; ANA, anti-nuclear antibody; anti-cent, anti-centromere antibody; anti-Scl70, anti-topoisomerase-1 antibody; NT-proBNP, N-terminal pro-B type natriuretic peptide; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; SD, standard deviation; SSc, systemic sclerosis.

ISSN: 1478-6362